FDA Inspection 1245768 — Oksana Hamidi, DO
The FDA completed an inspection of Oksana Hamidi, DO on Jul 18, 2024 in Dallas, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 18, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Dallas, TX (United States)
Additional Details
Clinical Investigator (CI)